drugset / Trial / NCT05084521
Interest of Famotidine in Children With Sickle Cell Disease
Phase 2/3
Completed
30 enrolled
Assistance Publique - Hôpitaux de Paris
INSERM U 1163 - Laboratory of molecular mechanisms of hematologic disorders and therapeutic implications, Paris · collabURC-CIC Paris Descartes Necker Cochin · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine whether oral famotidine, a histamine type 2 receptor antagonist already widely used with very few side effects in other indications in children, is effective in reducing endothelial expression of P-selectin in children with sickle cell disease (SCD). This pilot study will constitute the essential prerequisite for a randomized clinical trial comparing the efficacy of famotidine with that of placebo in the prevention of vaso-occlusive crises in SCD patients.
Timeline
- Start
- 2022-01-12
- Primary completion
- 2022-12-12
- Completion
- 2022-12-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Famotidine | Other / unclassified | 0.5 mg/kg | Oral |